Cargando…

IDH1 and IDH2 mutations in lung adenocarcinomas: Evidences of subclonal evolution

BACKGROUND: Selective IDH1 and IDH2 inhibitors have been approved for targeted therapy of acute myeloid leukemia. Clinical trials for solid tumors with IDH1 and IDH2 (IDH1/2) mutations are ongoing. Reports of IDH1/2‐mutated non–small cell lung cancers (NSCLCs), however, are limited. METHODS: We eval...

Descripción completa

Detalles Bibliográficos
Autores principales:	Rodriguez, Erika F., De Marchi, Federico, Lokhandwala, Parvez M., Belchis, Deborah, Xian, Rena, Gocke, Christopher D., Eshleman, James R., Illei, Peter, Li, Ming‐Tseh
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	John Wiley and Sons Inc. 2020
Materias:	Cancer Biology
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7300411/ https://www.ncbi.nlm.nih.gov/pubmed/32333643 http://dx.doi.org/10.1002/cam4.3058

Ejemplares similares

Heterogeneity of resistance mutations detectable by next-generation sequencing in TKI-treated lung adenocarcinoma
por: Belchis, Deborah A., et al.
Publicado: (2016)

The prognostic impact of subclonal IDH1 mutation in grade 2–4 astrocytomas
por: Vij, Meenakshi, et al.
Publicado: (2023)

Effect of IDH3a on glucose uptake in lung adenocarcinoma: A pilot study based on [(18)F]FDG
por: Du, Bulin, et al.
Publicado: (2019)

Clinical mutational profiling and categorization of BRAF mutations in melanomas using next generation sequencing
por: Lokhandwala, Parvez M., et al.
Publicado: (2019)

Clinical mutational profiling of 1006 lung cancers by next generation sequencing
por: Illei, Peter B., et al.
Publicado: (2017)

Gallbladder adenocarcinomas undergo subclonal diversification and selection from precancerous lesions to metastatic tumors
por: Kang, Minsu, et al.
Publicado: (2022)

Prognostic importance of IDH mutations in chondrosarcoma: An individual patient data meta‐analysis
por: Vuong, Huy Gia, et al.
Publicado: (2021)

Screen for IDH1, IDH2, IDH3, D2HGDH and L2HGDH Mutations in Glioblastoma
por: Krell, Daniel, et al.
Publicado: (2011)

Mutant IDH1 is required for IDH1 mutated tumor cell growth
por: Jin, Genglin, et al.
Publicado: (2012)

IDH1 and IDH2 mutations in myelodysplastic syndromes and role in disease progression
por: DiNardo, Courtney D, et al.
Publicado: (2015)

IDH1 and IDH2 mutations as novel therapeutic targets: current perspectives
por: Mondesir, Johanna, et al.
Publicado: (2016)

Oncogenetic landscape and clinical impact of IDH1 and IDH2 mutations in T-ALL
por: Simonin, Mathieu, et al.
Publicado: (2021)

Concurrent IDH1 and IDH2 mutations in glioblastoma: A case report
por: Haider, Ali S., et al.
Publicado: (2023)

Estimation of the occurrence rates of IDH1 and IDH2 mutations in gliomas and the reconsideration of IDH-wildtype anaplastic astrocytomas: an institutional experience
por: Cho, Uiju, et al.
Publicado: (2021)

Consequences of IDH1/2 Mutations in Gliomas and an Assessment of Inhibitors Targeting Mutated IDH Proteins
por: Kaminska, Bozena, et al.
Publicado: (2019)

The comparison of clinical and biological characteristics between IDH1 and IDH2 mutations in gliomas
por: Wang, Hao-Yuan, et al.
Publicado: (2016)

Acute myeloid leukemia with IDH1 and IDH2 mutations: 2021 treatment algorithm
por: Issa, Ghayas C., et al.
Publicado: (2021)

Clinical detection and categorization of uncommon and concomitant mutations involving BRAF
por: Zheng, Gang, et al.
Publicado: (2015)

IDH Mutations in Chondrosarcoma: Case Closed or Not?
por: Venneker, Sanne, et al.
Publicado: (2023)

IDH1/IDH2 but Not TP53 Mutations Predict Prognosis in Bulgarian Glioblastoma Patients
por: Stancheva, Gergana, et al.
Publicado: (2014)

Isocitrate Dehydrogenase IDH1 and IDH2 Mutations in Human Cancer: Prognostic Implications for Gliomas
por: Murugan, A. K., et al.
Publicado: (2022)

Secondary IDH1 resistance mutations and oncogenic IDH2 mutations cause acquired resistance to ivosidenib in cholangiocarcinoma
por: Cleary, James M., et al.
Publicado: (2022)

Identification of multiple subclones in peripheral T-cell lymphoma, not otherwise specified with genomic aberrations
por: Yoshida, Noriaki, et al.
Publicado: (2012)

IDH1/IDH2 Inhibition in Acute Myeloid Leukemia
por: Cerchione, Claudio, et al.
Publicado: (2021)

The prognostic IDH1(R132) mutation is associated with reduced NADP(+)-dependent IDH activity in glioblastoma
por: Bleeker, Fonnet E., et al.
Publicado: (2010)

Novel Multiplex Bead-Based Assay for Detection of IDH1 and IDH2 Mutations in Myeloid Malignancies
por: Shivarov, Velizar, et al.
Publicado: (2013)

CLINICAL AND BIOLOGICAL IMPLICATIONS OF ANCESTRAL AND NON-ANCESTRAL IDH1 AND IDH2 MUTATIONS IN MYELOID NEOPLASMS
por: Molenaar, Remco J., et al.
Publicado: (2015)

Analysis of ALK, IDH1, IDH2 and MMP8 somatic mutations in differentiated thyroid cancers
por: Murugan, Avaniyapuram Kannan, et al.
Publicado: (2021)

Targeting IDH1 and IDH2 Mutations in Acute Myeloid Leukemia: Emerging Options and Pending Questions
por: Wouters, Bas J.
Publicado: (2021)

Mismatch repair protein mutations in isocitrate dehydrogenase (IDH)-mutant astrocytoma and IDH-wild-type glioblastoma
por: Richardson, Timothy E, et al.
Publicado: (2023)

Molecular profile and its clinical impact of IDH1 mutated versus IDH1 wild type intrahepatic cholangiocarcinoma
por: Rimini, Margherita, et al.
Publicado: (2022)

Multiregional radiomics profiling from multiparametric MRI: Identifying an imaging predictor of IDH1 mutation status in glioblastoma
por: Li, Zhi‐Cheng, et al.
Publicado: (2018)

Ras/MAPK signalling intensity defines subclonal fitness in a mouse model of hepatocellular carcinoma
por: Lozano, Anthony, et al.
Publicado: (2023)

Non-IDH1-R132H IDH1/2 mutations are associated with increased DNA methylation and improved survival in astrocytomas, compared to IDH1-R132H mutations
por: Tesileanu, C. Mircea S., et al.
Publicado: (2021)

Distinct and opposite effects of leukemogenic Idh and Tet2 mutations in hematopoietic stem and progenitor cells
por: Fortin, Jerome, et al.
Publicado: (2023)

Mutations in IDH1, IDH2, and in the TERT promoter define clinically distinct subgroups of adult malignant gliomas
por: Killela, Patrick J., et al.
Publicado: (2014)

IDH1/IDH2 Mutations Define the Prognosis and Molecular Profiles of Patients with Gliomas: A Meta-Analysis
por: Zou, Peng, et al.
Publicado: (2013)

A Noninvasive Comparison Study between Human Gliomas with IDH1 and IDH2 Mutations by MR Spectroscopy
por: Shen, Xin, et al.
Publicado: (2019)

Impact of IDH1 and IDH2 mutational subgroups in AML patients after allogeneic stem cell transplantation
por: Kunadt, Desiree, et al.
Publicado: (2022)

Implications of Concurrent IDH1 and IDH2 Mutations on Survival in Glioma—A Case Report and Systematic Review
por: Yuile, Alexander, et al.
Publicado: (2022)

Cannot write session to /tmp/vufind_sessions/sess_pij8fj6jgrphqtm4lm90ipkeur